Navigation Links
Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE® Pediatric Ulcerative Colitis Indication
Date:12/29/2010

ing, and eliminating corticosteroid use in patients with moderately to severely active UC who have had an inadequate response to conventional therapy.
  • Reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function in patients with PsA.  
  • Treatment of adult patients with chronic severe plaque PsO who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.

  • REMICADE is unique among available anti-TNF biologic therapies.  It is the only anti-TNF biologic administered directly by caregivers in the clinic or office setting.  REMICADE is a two-hour infusion administered every 4 or 8 weeks (indication-dependent), following a standard induction regimen that requires treatment at weeks 0, 2 and 6.  As a result, REMICADE patients may require as few as six treatments each year as maintenance therapy.

    Centocor Ortho Biotech Inc. discovered and developed REMICADE and has exclusive marketing rights to the product in the United States.  

    Important Safety Information  

    Only a doctor can recommend a course of treatment after checking a patient's health condition. REMICADE® (infliximab) can cause serious side effects such as lowering your ability to fight infections. There are reports of serious infections caused by viruses, fungi or bacteria that have spread throughout the body, including tuberculosis (TB) and histoplasmosis. Some of these infections have been fatal. Your doctor should monitor you closely for signs and symptoms of TB during treatment with REMICADE®.

    Unusual cancers have been reported in children and teenage patients taking TNF-blocker medicines. A rare form of fatal lymphoma has occurred mostly in teenage or young adult males with Crohn's disease or ulcerative colitis who were taking REMICADE® and azathioprine or 6-mercaptopurine.
    '/>"/>

    SOURCE Centocor Ortho Biotech Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
    2. Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotechs New Psoriasis Agent Stelara (ustekinumab) is High
    3. Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI® Label to Include Inhibition of Structural Damage in Treatment of Psoriatic Arthritis
    4. Centocor Ortho Biotech Inc. Announces NDA Submission for Abiraterone Acetate for the Treatment of Metastatic Advanced Prostate Cancer
    5. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
    6. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
    7. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
    8. Clinical Data Presented on OrthoGlide(R) Medial Knee Implant
    9. ORTHO EVRA(R) Prescribing Information Updated
    10. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
    11. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... Sept. 30, 2014  Tasly Pharmaceuticals, Inc., the ... medicine, announced today the launch of Deepure. ... to address men and women concerned with supporting ... into old age while helping keep their health ... whole-food and herb-based formulas, namely, ProHeart PLUS, ImmunoPower ...
    (Date:9/30/2014)... NEW YORK , Sept. 30, 2014 /PRNewswire/ ... - 2014 Summary Global Markets Direct,s, ... 2014, provides an overview of the Aileron Therapeutics, ... report provides comprehensive information on the current therapeutic ... comparative analysis at various stages, therapeutics assessment by ...
    (Date:9/30/2014)... According to the ... Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments (HPLC, ... (Immunology, Oncology) & by End User - ... provides a detailed overview of the major ... and strategies impacting the global glycomics enzymes, ...
    Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
    ... July 2 Acura Pharmaceuticals, Inc. (Nasdaq: ACUR ... announced today that the U.S. Food and Drug Administration (FDA) ... Application (NDA) for Acurox (oxycodone HC1, USP and niacin, USP) ... of moderate-to-severe pain. , , (Logo: ...
    ... REYKJAVIK, Iceland, July 1 The largest study of,the genetics ... in the sequence of the human genome (SNPs) linked to,risk ... scientists,led by a team from deCODE genetics (Nasdaq: DCGN ... participants from fourteen countries.,It is published today in the online ...
    Cached Medicine Technology:Acura and King Receive FDA Complete Response Letter Regarding Acurox(R) 2Acura and King Receive FDA Complete Response Letter Regarding Acurox(R) 3deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 2deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 3deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 4deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 5
    (Date:10/1/2014)... 2014 Patients with increased inflammation, including those ... increased risk of depression. For example, a 6-month ... C virus infection causes depression in approximately 30% ... commonly known as fish oil, have a long ... of heart disease and reducing triglyceride levels. These ...
    (Date:10/1/2014)... 2014 Insuranceragents.info has released a ... life insurance plan for vulnerable family members. , Life ... members. Providers in the family should always carry a ... hardships for the rest of the family. , ... can benefit more from temporary coverage or from a ...
    (Date:10/1/2014)... 01, 2014 T.E.N., a ... relationship-marketing firm, announced today the nominees vying ... Project of the Year Awards for North ... organizations in financial services, commercial, health care, ... endeavors that address key issues in the ...
    (Date:10/1/2014)... Between 23 million and 50 million ... to figures from the National Institutes of Health (NIH) ... many of them have something else in common: They ... disease. Gluten Free Therapeutics, makers of CeliVites ... disease by publishing a series of blog posts aimed ...
    (Date:10/1/2014)... Scientists at the University of Western Australia say ... proteins has the power to knock out mesothelioma in ... new study on their website. Click here to ... UWA School of Pathology and Laboratory Medicine administered anti-CD25, ... with promising results. , “A timed triple immunotherapy ...
    Breaking Medicine News(10 mins):Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2
    ... Beverage by Health Magazine, SEATTLE, June 5 ... its Yellow Mango Orchard natural 100 percent juice,blend have ... by Health,Magazine., With the help of top health ... food and fitness to the ultimate test,and unveiled a ...
    ... MRI for evaluating new drugs, study says , , ... can cheaply and easily track how effective some cancer ... by using the same gene that gives fireflies their ... (BLI), the University of Teexas Southwestern Medical Center team ...
    ... by The Massachusetts School of,Professional Psychology, WEST ... this state about the ,invisible wounds of war, ... stress, depression and post traumatic,stress disorder (PTSD) - ... violence and suicide. We need to begin focusing ...
    ... PARK, Md., June 5 Dynasplint Systems, Inc. --, ... 34th annual,Severna Park Independence Day Parade and Festival. Held ... at St. Martin,s -in-the-field and,Our Shepherd Lutheran churches on ... and family activities at Cypress Creek Park., This ...
    ... World,s top equine veterinarians perform leading-edge techniques ... the lives of both,horses and humans, ... for,Biomedical Research (FBR) releases its feature film ... veterinarians, Dr. Larry Bramlage (Rood & Riddle,Equine ...
    ... fourth-quarter fiscal 2008 ... ... Corporation,(NYSE: MDP ), one of America,s leading media and marketing ... firm. Additionally, the company provided a,business update, and announced it will ...
    Cached Medicine News:Health News:Kagome's Yellow Mango Orchard Blended Juice Named One of America's Healthiest Buys 2Health News:Kagome's Yellow Mango Orchard Blended Juice Named One of America's Healthiest Buys 3Health News:Tracking Cancer Drug's Effectiveness 2Health News:Growing Public Health Crisis of Domestic Violence and Suicides by Returning Veterans 2Health News:The Foundation for Biomedical Research (FBR) Releases Feature DVD Majestic for World Premiere 2Health News:Meredith Expands Integrated Marketing Capabilities by Acquiring Top Healthcare Marketing Communications Firm 2Health News:Meredith Expands Integrated Marketing Capabilities by Acquiring Top Healthcare Marketing Communications Firm 3Health News:Meredith Expands Integrated Marketing Capabilities by Acquiring Top Healthcare Marketing Communications Firm 4Health News:Meredith Expands Integrated Marketing Capabilities by Acquiring Top Healthcare Marketing Communications Firm 5
    ... over a wide range of concentration, ... more thorough characterization than other methods. ... relative change in the distribution of ... to measure heterogeneity, stoichiometry and self-associating ...
    Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
    Alkaline phosphatase FS (DGKC new; 37C). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
    For the quantitative determination of alkaline phosphatase in human serum....
    Medicine Products: